Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice

Antimicrob Agents Chemother. 2003 Aug;47(8):2685-7. doi: 10.1128/AAC.47.8.2685-2687.2003.

Abstract

In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 micro g/ml or lower. In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens. A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Aza Compounds*
  • Colony Count, Microbial
  • Drug Therapy, Combination
  • Fluoroquinolones*
  • Humans
  • Liver / microbiology
  • Mice
  • Mice, Inbred C57BL
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Mycobacterium avium Complex*
  • Mycobacterium avium-intracellulare Infection / drug therapy*
  • Mycobacterium avium-intracellulare Infection / microbiology
  • Quinolines*
  • Spleen / microbiology
  • Thioacetazone / analogs & derivatives*
  • Thioacetazone / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • SRI 224
  • SRI 286
  • Thioacetazone
  • Moxifloxacin